Ignite Creation Date:
2024-05-06 @ 2:44 PM
Last Modification Date:
2024-10-26 @ 1:36 PM
Study NCT ID:
NCT04401761
Status:
COMPLETED
Last Update Posted:
2023-10-25
First Post:
2020-05-22
Brief Title:
A Study to Collect Data on the Treatment Pattern of Xarelto Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and or a Condition That Most Commonly Narrows the Blood Vessel in the Legs
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Xarelto Acetylsalicylic Acid Treatment Patterns and Outcomes Across the Disease Continuum in Patients With CAD andor PAD
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
XATOC
Brief Summary:
The study will focus on effectiveness and safety of rivaroxaban Xarelto when given together with acetylsalicylic acid combination therapy to patients suffering from coronary artery disease a condition that affects the blood vessels supplying the heart and or peripheral artery disease a condition that affects the blood vessels of the lower limbs in the routine clinical practice The study will help to collect data for prevention cardiovascular death myocardial infarction MI stroke and major adverse limb events in adult patients The study will focus on information on when and why physicians are starting to treat patients with combination therapy treatment duration reasons to discontinue treatment and previous therapies The study will also investigate treatment outcomes for patients being treated with a combination therapy by their physicians
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None